Overview

Evaluation of Curcumin's Effect on Inflammation in Hemodialysis Patients

Status:
Completed
Trial end date:
2017-02-02
Target enrollment:
0
Participant gender:
All
Summary
Programmed ingestion of turmeric has no adverse effects and reduces plasma level of hs-CRP, IL-6 and TNF-α accompanying with increases albumin levels in hemodialysis patients. Turmeric can be considered as an effective anti-inflammatory supplement in hemodialysis patients.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Treatments:
Curcumin
Criteria
Inclusion Criteria:• Males or females undergoing maintenance hemodyalisis,

- Age ≥18 year

- Clinically stable and receiving adequate hemodialysis defined by a single pool
Kt/V≥1.20 or no less than 3 dialysis sessions per week with a total dialysis time ≥12
hour per week for at least 3 month before enrollment,

- Diabetic patients must be willing to commence insulin therapy if deemed necessary for
plasma glucose control.

Exclusion Criteria:

- Active malignant disease (defined as less than 5 year since receiving a diagnosis of
being malignancy-free)

- Critical illness as defined by the need for respiratory or circulatory support
(in an intensive care unit)

- Active vasculitis

- Severe congestive heart failure (New York Heart Association class IV)

- Severe chronic systemic infectious or inflammatory disease

- Liver disease (defined as serum alanine aminotransferase or aspartate
aminotransferase levels greater than three times the upper limit of normal)

- Known or suspected allergy to trial product(s) or related products

- Treatment with immunosuppressive agents or receipt of any investigational drug
within one month preceding screening

- Recent or current use of anti-inflammatory corticosteroids agents

- A scheduled renal transplantation within the trial period